首页 | 本学科首页   官方微博 | 高级检索  
检索        


Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010–2014
Institution:1. National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain;2. CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain;3. Institute of Health Carlos III, National Centre for Microbiology, National Influenza Centre, 28220 Majadahonda, Madrid, Spain;1. Instituto de Salud Pública de Navarra, IdiSNA–Navarra Institute for Health Research, Pamplona, Spain;2. CIBER Epidemiología y Salud Pública (CIBERESP), Spain;3. Complejo Hospitalario de Navarra, IdiSNA–Navarra Institute for Health Research, Pamplona, Spain;4. Clínica Universidad de Navarra, IdiSNA–Navarra Institute for Health Research, Pamplona, Spain;5. Centro Nacional de Microbiología (WHO National Influenza Centre–Madrid), Instituto de Salud Carlos III, Majadahonda, Spain;1. GSK, Wavre, Belgium;2. icddr,b, Dhaka, Bangladesh;3. American University of Beirut, Beirut, Lebanon;4. GSK, King of Prussia, PA, USA;5. GSK, Rockville, MD, USA;6. Khon Kaen University, Khon Kaen, Thailand;7. National Autonomous University of Santo Domingo, Santo Domingo, Dominican Republic;8. Dr Castroviejo Primary Health Care Center, Madrid, Spain;9. Complutense University of Madrid, Madrid, Spain;10. Jaume I University and Illes Columbretes Health Center of Castellón, Castellón de la Plana, Spain;11. Tecnologia en Investigacion, San Pedro Sula, Honduras;12. National Autonomous University of Honduras, Tegucigalpa, Honduras;13. FISABIO-Public Health, Valencia, Spain;14. Eskisehir Osmangazi University, Eskisehir, Turkey;15. University of Southampton, Southampton, UK;p. University Hospital Southampton NHS Foundation Trust, Southampton, UK;q. Hospital Infantil Universitario La Paz, Madrid, Spain;r. Mary Chiles General Hospital, Manila, Philippines;s. University of the Philippines—Philippine General Hospital, Manila, Philippines;t. Royal Manchester Children''s Hospital, Manchester, UK;u. Center of Postgraduate Medical Education, Warsaw, Poland;v. Centre for Community Medicine, All India institute of Medical Sciences, New Delhi, India;w. Research Institute for Tropical Medicine, Manila, Philippines;x. Paediatric Institute Mares-Riera, Blanes, Spain;y. Hospital Clínico Universitario de Santiago, Santiago, Spain;z. Hospital of Antequera, Malaga, Spain;11. EAP Sardenya-IIB Sant Pau, Barcelona, Spain;12. University of Hradec Kralove, Hradec Kralove, Czech Republic;13. Chulalongkorn University, Bangkok, Thailand;14. Medicentrum 6 s.r.o., Prague, Czech Republic;15. Nicolaus Copernicus University in Torun, Collegium Medicum, Bydgoszcz, Poland;16. University Hospital No 2, Bydgoszcz, Poland;17. Instituto Hispalense de Pediatría, Sevilla, Spain;18. Catholic University of Louvain, Cliniques Universitaires St Luc, Brussels, Belgium;19. GSK, Bangalore, India;110. St Hedwig of Silesia Hospital, Trzebnica, Poland;111. EBA Centelles, Barcelona, Spain;1. University of Antwerp, Antwerpen, Belgium;2. Center for Statistics, Hasselt University, Martelarenlaan 42, Hasselt, 3500, Belgium;1. Istituto Superiore di Sanità, Rome, Italy;2. Dipartimento Scienze biomediche ed oncologia umana, Università degli Studi di Bari Aldo Moro, Bari, Italy;3. Dipartimento di Scienze biomediche per la salute, Università degli Studi di Milano, Milan, Italy;4. Governo della Prevenzione e tutela sanitaria, Regione Lombardia, Milan, Italy;5. SeREMI ASL AL, Servizio Riferimento Regionale, Epidemiologia Malattie Infettive, Alessandria, Italy;6. Ospedale “Amedeo di Savoia”- Torino, Italy;7. Servizio Sanità pubblica, D. G. Sanità e Politiche sociali, Regione Emilia-Romagna, Bologna, Italy;8. Dipartimento di Scienze Biomediche, Biotecnologiche e Traslazionali, Università degli Studi di Parma, Italy;1. Department of Virus and Microbiological Special diagnostics, National Influenza Center, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark;2. Department of Infectious Diseases and Centre for Global Health, Clinical Institute, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark;3. Department of Infectious Disease Epidemiology & Prevention, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark;4. Department of Clinical Microbiology, Herlev Hospital, Herlev Ringvej 75, 2730 Herlev, Denmark;5. Department of Clinical Microbiology, Slagelse Hospital, Ingemannsvej 18, 4200 Slagelse, Denmark;6. Department of Clinical Microbiology, Aalborg University Hospital, Hobrovej 18-22, 9100 Aalborg, Denmark;7. Department of Clinical Microbiology, Vejle Sygehus, Beriderbakken 4, 7100 Vejle, Denmark;8. Department of Clinical Microbiology, Odense University Hospital, Søndre Blvd. 29, 5000 Odense C, Denmark;9. Department of Clinical Microbiology, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Denmark
Abstract:IntroductionThe agreement between interim and final influenza vaccine effectiveness (VE) estimates would support the use of interim assessments as a proxy for final VE results to guide health authorities in influenza prevention. We aimed to compare interim/final VE estimates in Spain.MethodsWe used a test-negative case-control study (cycEVA) for 2010/11–2013/14 seasons. Sensitivity analyses were carried out by type/subtype of influenza virus and by target groups for vaccination.ResultsIn general, interim estimates were higher compared to end-season estimates. Interim and final VE differences were higher for the target groups compared to all population. Subtype-specific interim/final VE estimates showed greater concordance (3–13%) than for any virus (7–24%).ConclusionIn Spain, interim influenza VE estimates over 2010–2014 were a good proxy of the final protection of the vaccine. Interim and final estimates showed greater concordance for all population and if performed subtype-specific.
Keywords:Influenza  Vaccine effectiveness  Interim analysis  Case-control studies  Sentinel networks
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号